2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Sell
41
OCUL Quote, Financials, Valuation and Earnings
Last price:
$7.95
Seasonality move
:
-9.47%
Day range:
$7.72 - $8.14
52-week range:
$4.06 - $11.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.17x
P/B ratio:
3.89x
Volume:
1.4M
Avg. volume:
1.3M
1-year change:
-16.63%
Market cap:
$1.2B
Revenue:
$63.7M
EPS (TTM):
-$1.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OCUL
Ocular Therapeutix
|
$16.9M | -$0.22 | 16.58% | -42.86% | $17.50 |
|
ADMA
ADMA Biologics
|
$112.8M | $0.15 | 41.07% | 75% | $25.27 |
|
CARA
Cara Therapeutics
|
$1.6M | -$2.94 | -73.37% | -83.05% | $12.00 |
|
EYPT
EyePoint Pharmaceuticals
|
$11M | -$0.48 | -24.38% | -22.59% | $33.00 |
|
OCGN
Ocugen
|
$300K | -$0.05 | -100% | -- | $6.75 |
|
TGTX
TG Therapeutics
|
$100.7M | $0.20 | 84.44% | -95.36% | $42.83 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OCUL
Ocular Therapeutix
|
$7.72 | $17.50 | $1.2B | -- | $0.00 | 0% | 19.17x |
|
ADMA
ADMA Biologics
|
$18.43 | $25.27 | $4.4B | 22.48x | $0.00 | 0% | 10.47x |
|
CARA
Cara Therapeutics
|
$5.13 | $12.00 | $23.5M | -- | $0.00 | 0% | 3.28x |
|
EYPT
EyePoint Pharmaceuticals
|
$6.52 | $33.00 | $448.1M | -- | $0.00 | 0% | 8.48x |
|
OCGN
Ocugen
|
$0.54 | $6.75 | $156.9M | -- | $0.00 | 0% | 35.90x |
|
TGTX
TG Therapeutics
|
$40.84 | $42.83 | $6.4B | 291.71x | $0.00 | 0% | 19.45x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OCUL
Ocular Therapeutix
|
17.85% | 3.384 | 5.09% | 10.26x |
|
ADMA
ADMA Biologics
|
17.17% | 4.789 | 1.78% | 2.76x |
|
CARA
Cara Therapeutics
|
-- | -3.732 | -- | 10.67x |
|
EYPT
EyePoint Pharmaceuticals
|
-- | -2.597 | -- | 7.57x |
|
OCGN
Ocugen
|
49.18% | 4.395 | 12.22% | 2.71x |
|
TGTX
TG Therapeutics
|
52.36% | 3.612 | 5.21% | 4.85x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OCUL
Ocular Therapeutix
|
$15.9M | -$50.6M | -51.22% | -62.66% | -265.09% | -$39.6M |
|
ADMA
ADMA Biologics
|
$63.3M | $38.3M | 60.85% | 93.41% | 31.98% | $23.9M |
|
CARA
Cara Therapeutics
|
$1.5M | -$5.5M | -374.56% | -374.56% | -374.98% | -$4M |
|
EYPT
EyePoint Pharmaceuticals
|
$10.8M | -$45.2M | -50.34% | -50.34% | -356.36% | -$36.2M |
|
OCGN
Ocugen
|
-- | -$13.8M | -136.46% | -171.04% | -1811.52% | -$10.4M |
|
TGTX
TG Therapeutics
|
$92.8M | $29.9M | 6.86% | 12.81% | 30.05% | -$25.7M |
Ocular Therapeutix vs. Competitors
-
Which has Higher Returns OCUL or ADMA?
ADMA Biologics has a net margin of -283.27% compared to Ocular Therapeutix's net margin of 95.19%. Ocular Therapeutix's return on equity of -62.66% beat ADMA Biologics's return on equity of 93.41%.
Company Gross Margin Earnings Per Share Invested Capital OCULOcular Therapeutix92.8% -$0.29 $383.8M ADMAADMA Biologics53.88% $0.46 $421.4M -
What do Analysts Say About OCUL or ADMA?
Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 126.68%. On the other hand ADMA Biologics has an analysts' consensus of $25.27 which suggests that it could grow by 37.13%. Given that Ocular Therapeutix has higher upside potential than ADMA Biologics, analysts believe Ocular Therapeutix is more attractive than ADMA Biologics.
Company Buy Ratings Hold Ratings Sell Ratings OCULOcular Therapeutix5 0 0 ADMAADMA Biologics4 0 0 -
Is OCUL or ADMA More Risky?
Ocular Therapeutix has a beta of 1.337, which suggesting that the stock is 33.685% more volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.509%.
-
Which is a Better Dividend Stock OCUL or ADMA?
Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OCUL or ADMA?
Ocular Therapeutix quarterly revenues are $17.1M, which are smaller than ADMA Biologics quarterly revenues of $117.5M. Ocular Therapeutix's net income of -$48.4M is lower than ADMA Biologics's net income of $111.9M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while ADMA Biologics's PE ratio is 22.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.17x versus 10.47x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OCULOcular Therapeutix19.17x -- $17.1M -$48.4M ADMAADMA Biologics10.47x 22.48x $117.5M $111.9M
-
Which has Higher Returns OCUL or CARA?
Cara Therapeutics has a net margin of -283.27% compared to Ocular Therapeutix's net margin of -527.77%. Ocular Therapeutix's return on equity of -62.66% beat Cara Therapeutics's return on equity of -374.56%.
Company Gross Margin Earnings Per Share Invested Capital OCULOcular Therapeutix92.8% -$0.29 $383.8M CARACara Therapeutics70.96% -$1.73 -$4.6M -
What do Analysts Say About OCUL or CARA?
Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 126.68%. On the other hand Cara Therapeutics has an analysts' consensus of $12.00 which suggests that it could grow by 133.92%. Given that Cara Therapeutics has higher upside potential than Ocular Therapeutix, analysts believe Cara Therapeutics is more attractive than Ocular Therapeutix.
Company Buy Ratings Hold Ratings Sell Ratings OCULOcular Therapeutix5 0 0 CARACara Therapeutics0 1 0 -
Is OCUL or CARA More Risky?
Ocular Therapeutix has a beta of 1.337, which suggesting that the stock is 33.685% more volatile than S&P 500. In comparison Cara Therapeutics has a beta of 0.499, suggesting its less volatile than the S&P 500 by 50.057%.
-
Which is a Better Dividend Stock OCUL or CARA?
Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cara Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Cara Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OCUL or CARA?
Ocular Therapeutix quarterly revenues are $17.1M, which are larger than Cara Therapeutics quarterly revenues of $1.5M. Ocular Therapeutix's net income of -$48.4M is lower than Cara Therapeutics's net income of -$7.7M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Cara Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.17x versus 3.28x for Cara Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OCULOcular Therapeutix19.17x -- $17.1M -$48.4M CARACara Therapeutics3.28x -- $1.5M -$7.7M
-
Which has Higher Returns OCUL or EYPT?
EyePoint Pharmaceuticals has a net margin of -283.27% compared to Ocular Therapeutix's net margin of -357.26%. Ocular Therapeutix's return on equity of -62.66% beat EyePoint Pharmaceuticals's return on equity of -50.34%.
Company Gross Margin Earnings Per Share Invested Capital OCULOcular Therapeutix92.8% -$0.29 $383.8M EYPTEyePoint Pharmaceuticals92.96% -$0.64 $336.5M -
What do Analysts Say About OCUL or EYPT?
Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 126.68%. On the other hand EyePoint Pharmaceuticals has an analysts' consensus of $33.00 which suggests that it could grow by 406.14%. Given that EyePoint Pharmaceuticals has higher upside potential than Ocular Therapeutix, analysts believe EyePoint Pharmaceuticals is more attractive than Ocular Therapeutix.
Company Buy Ratings Hold Ratings Sell Ratings OCULOcular Therapeutix5 0 0 EYPTEyePoint Pharmaceuticals9 0 0 -
Is OCUL or EYPT More Risky?
Ocular Therapeutix has a beta of 1.337, which suggesting that the stock is 33.685% more volatile than S&P 500. In comparison EyePoint Pharmaceuticals has a beta of 1.409, suggesting its more volatile than the S&P 500 by 40.932%.
-
Which is a Better Dividend Stock OCUL or EYPT?
Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. EyePoint Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OCUL or EYPT?
Ocular Therapeutix quarterly revenues are $17.1M, which are larger than EyePoint Pharmaceuticals quarterly revenues of $11.6M. Ocular Therapeutix's net income of -$48.4M is lower than EyePoint Pharmaceuticals's net income of -$41.4M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while EyePoint Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.17x versus 8.48x for EyePoint Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OCULOcular Therapeutix19.17x -- $17.1M -$48.4M EYPTEyePoint Pharmaceuticals8.48x -- $11.6M -$41.4M
-
Which has Higher Returns OCUL or OCGN?
Ocugen has a net margin of -283.27% compared to Ocular Therapeutix's net margin of -1816.75%. Ocular Therapeutix's return on equity of -62.66% beat Ocugen's return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital OCULOcular Therapeutix92.8% -$0.29 $383.8M OCGNOcugen-- -$0.05 $58.3M -
What do Analysts Say About OCUL or OCGN?
Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 126.68%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 1156.28%. Given that Ocugen has higher upside potential than Ocular Therapeutix, analysts believe Ocugen is more attractive than Ocular Therapeutix.
Company Buy Ratings Hold Ratings Sell Ratings OCULOcular Therapeutix5 0 0 OCGNOcugen2 0 0 -
Is OCUL or OCGN More Risky?
Ocular Therapeutix has a beta of 1.337, which suggesting that the stock is 33.685% more volatile than S&P 500. In comparison Ocugen has a beta of 3.883, suggesting its more volatile than the S&P 500 by 288.285%.
-
Which is a Better Dividend Stock OCUL or OCGN?
Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OCUL or OCGN?
Ocular Therapeutix quarterly revenues are $17.1M, which are larger than Ocugen quarterly revenues of $764K. Ocular Therapeutix's net income of -$48.4M is lower than Ocugen's net income of -$13.9M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.17x versus 35.90x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OCULOcular Therapeutix19.17x -- $17.1M -$48.4M OCGNOcugen35.90x -- $764K -$13.9M
-
Which has Higher Returns OCUL or TGTX?
TG Therapeutics has a net margin of -283.27% compared to Ocular Therapeutix's net margin of 21.57%. Ocular Therapeutix's return on equity of -62.66% beat TG Therapeutics's return on equity of 12.81%.
Company Gross Margin Earnings Per Share Invested Capital OCULOcular Therapeutix92.8% -$0.29 $383.8M TGTXTG Therapeutics85.77% $0.15 $466.8M -
What do Analysts Say About OCUL or TGTX?
Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 126.68%. On the other hand TG Therapeutics has an analysts' consensus of $42.83 which suggests that it could grow by 4.88%. Given that Ocular Therapeutix has higher upside potential than TG Therapeutics, analysts believe Ocular Therapeutix is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings OCULOcular Therapeutix5 0 0 TGTXTG Therapeutics5 0 0 -
Is OCUL or TGTX More Risky?
Ocular Therapeutix has a beta of 1.337, which suggesting that the stock is 33.685% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.303, suggesting its more volatile than the S&P 500 by 130.31%.
-
Which is a Better Dividend Stock OCUL or TGTX?
Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OCUL or TGTX?
Ocular Therapeutix quarterly revenues are $17.1M, which are smaller than TG Therapeutics quarterly revenues of $108.2M. Ocular Therapeutix's net income of -$48.4M is lower than TG Therapeutics's net income of $23.3M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 291.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.17x versus 19.45x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OCULOcular Therapeutix19.17x -- $17.1M -$48.4M TGTXTG Therapeutics19.45x 291.71x $108.2M $23.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Ford Stock Undervalued Amid the EV Transition?
There is a lot going on in the electric vehicle…
Is Goldman Sachs Stock a Buy Sell or Hold?
When the Federal Reserve started hiking rates in 2022, banks’…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
49
SMTC alert for Mar 17
Semtech [SMTC] is down 0.49% over the past day.
Buy
62
PLPC alert for Mar 17
Preformed Line Products [PLPC] is up 3.8% over the past day.
Sell
50
NUTX alert for Mar 17
Nutex Health [NUTX] is up 4.82% over the past day.
